BriaCell Therapeutics Corp
BriaCell Therapeutics Corp.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • BriaCell (BCT) has signed an agreement with Waisman Biomanufacturing to manufacture Bria-Pros for BriaCell’s anticipated clinical trial in advanced prostate cancer
  • Bria-Pros is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer
  • Waisman is a leading contract manufacturing organization with experience in the manufacturing of cellular therapies for clinical trials
  • BriaCell is an immuno-oncology focused biotechnology company which develops targeted and effective approach to managing cancer
  • BriaCell Therapeutics Corp. (BCT) was up 9.21 per cent, trading at C$8.18 per share at 11:55 am ET

BriaCell (BCT) has signed an agreement with Waisman Biomanufacturing to manufacture Bria-Pros for BriaCell’s anticipated clinical trial in advanced prostate cancer.

Bria-Pros is a novel off-the-shelf personalized immunotherapy approach to treating prostate cancer. It includes multiple Human leukocyte antigen (HLA)-specific immunotherapy cell lines. It will be administered to patients based on each patient’s HLA type. BriaCell has been developing Bria-Pros as a potentially safe and effective personalized immunotherapy treatment for advanced prostate cancer.

Waisman is a leading contract manufacturing organization with experience in the manufacturing of cellular therapies for clinical trials. Under the terms of the agreement, Waisman will be responsible for good manufacturing practice (GMP) manufacturing of Bria-Pros for anticipated use in clinical studies.

Waisman’s expert team will be working closely with BriaCell’s scientific and product development teams to ensure timely production of Bria-Pros and in compliance with applicable regulatory requirements by the FDA.

The company expects to start Phase I/II trial in prostate cancer upon completion of the manufacturing, testing, and the related regulatory filings.

According to 2022 Cancer Facts & Figures, aside from lung cancer, prostate cancer is the most common cancer among men. Current treatments for metastatic prostate cancer include immunotherapy, hormone therapy, chemotherapy and targeted treatments. 

BriaCell is an immuno-oncology focused biotechnology company which develops targeted and effective approach to managing cancer.

BriaCell Therapeutics Corp. (BCT) was up 9.21 per cent, trading at C$8.18 per share at 11:55 am ET.

More From The Market Herald

" Update from Revive Therapeutics (CSE:RVV) on Phase 3 clinical trial for Bucillamine in COVID-19

Revive Therapeutics (RVV) has provided an update on the company’s U.S. Food & Drug Administration (FDA) Phase 3 clinical trial.

" Core One Labs (CSE:COOL) subsidiary Vocan successfully converts Psilocin precursor into Psilocybin

Core One Labs (CSE:COOL) subsidiary Vocan Biotechnologies has converted psilocin developed by Awakened Biosciences into viable API psilocybin.

" Small Pharma (TSXV:DMT) receives approval for DMT-assisted psychotherapy & SSRI drug study

Small Pharma (DMT) has received approval to initiate a drug interaction clinical trial in the U.K.

" Kovo HealthTech (TSXV:KOVO) sees 211 per cent year-over-year revenue growth

Kovo HealthTech Corp. (KOVO) reported its Q2 financial results for the period ending June 30, 2022.